Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 2.2% – Still a Buy?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)’s stock price traded up 2.2% during mid-day trading on Thursday . The company traded as high as $1.42 and last traded at $1.42. Approximately 109,808 shares changed hands during trading, an increase of 20% from the average daily volume of 91,223 shares. The stock had previously closed at $1.39.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Wall Street Zen raised Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Up 1.4%

The stock’s fifty day moving average price is $1.60 and its 200 day moving average price is $2.29. The stock has a market cap of $6.19 million, a PE ratio of -0.36 and a beta of -2.05.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.03). On average, equities research analysts expect that Acurx Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Acurx Pharmaceuticals during the fourth quarter valued at $27,000. Geode Capital Management LLC bought a new stake in Acurx Pharmaceuticals in the 4th quarter worth about $31,000. Millennium Management LLC bought a new stake in Acurx Pharmaceuticals in the 4th quarter worth about $103,000. Finally, Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals in the 2nd quarter worth about $551,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).